Lion Biotechnologies to Participate in Upcoming Investor Conferences
May 19 2015 - 8:00AM
Lion Biotechnologies, Inc. (Nasdaq:LBIO) today announced that
president and CEO Elma Hawkins, PhD, will participate in the
following upcoming investor conferences:
Piper Jaffray GenomeRx
Symposium |
Date: Wednesday – Thursday, May 20-21,
2015 |
Panels: CAR-T: Engineering Lethal
Lymphocytes, May 20, 10:25 am; Cellular Therapies: Toolkits and
Platforms, May 20, 11:50 am |
Location: The New York Palace Hotel, New
York |
|
Sachs Immuno-Oncology BD&L and
Investment Forum |
Date: Friday, May 29, 2015 |
Panel: Immunotherapeutics: ADCs and
Combination Therapies – BD&L, May 29, 10:20 am |
Corporate Presentation: May 29, 1:30 pm |
Location: Hyatt Chicago Magnificent Mile,
Chicago |
|
Jefferies 2015 Healthcare
Conference |
Date: Monday – Thursday, June 1-4, 2015 |
Corporate Presentation: June 1, 10:00
am |
Location: Grand Hyatt, New York |
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T
cells and engineered T cells for the treatment of various
cancers. The company's lead product candidate is a
ready-to-infuse, autologous T-cell therapy utilizing
tumor-infiltrating lymphocytes (TIL) for the treatment of patients
with Stage 4 metastatic melanoma, and is based on a clinical
Cooperative Research and Development Agreement with the National
Cancer Institute. TIL therapy is also being evaluated in
physician-sponsored clinical trials at MD Anderson Cancer Center
and the H. Lee Moffitt Cancer Center & Research Institute. For
more information, please visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties described
in the Company's most recently filed quarterly report on Form 10-Q
and annual report on Form 10-K. Except as permitted by law, the
Company undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Investor Relations
The Trout Group
Elizabeth Broder
646-378-2945
ebroder@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024